Daily Briefing – June 13: SpaceX aftershock dominates risk appetite, Iran deal hopes cool oil, Fed week becomes the next market test

The June 13, 2026 briefing is a weekend update, so the key read is not a live cash-market session but the market’s positioning after Friday’s close. The tape ended the week with a relief tone: Wall Street finished higher as SpaceX’s record public debut dominated sentiment, while oil dropped on fresh hopes that the U.S. and Iran may be moving toward a deal around the Strait of Hormuz. The story is better than it was two days ago, but it is not clean. Reuters reports that U.S.-Iran negotiations may be nearing a framework, yet military activity near Hormuz has not fully disappeared. That means oil relief is real, but the geopolitical premium has not been erased. At the same time, the inflation backdrop is still uncomfortable: BLS data show May CPI at 4.2% year over year and core CPI at 2.9%, while May PPI showed final demand up 1.1%, goods up 2.8%, energy up 10.7% and final demand less foods, energy and trade services up 5.1% over 12 months. The next major market test is now the Federal Reserve meeting week, especially with investors focused on how the newly led Fed frames inflation, oil, financial conditions and the risk of another policy tightening cycle.

• SPCX— SpaceX is now the center of the risk-appetite debate after its Nasdaq debut. Reuters reported that the stock surged in its first session after the record IPO, helping Wall Street close higher, while retail demand became one of the most important features of the first trading day.Space IPO
• RKLB / LUNR / PL / SATL— The public space basket is now in the post-SpaceX reality check. A strong SPCX debut proved that investors still want the space narrative, but several public space names were weaker after rallying ahead of the IPO. That makes follow-through more important than the headline.Space Basket
• ORCL— Oracle remains the key AI capex lesson. The company’s massive cloud backlog keeps the AI infrastructure story alive, but investors are still debating how much debt, capex and negative free cash flow the market will tolerate for cloud growth.AI Capex
• NVDA— Nvidia remains the anchor of the AI trade, but the market is now more selective. The cleaner trade is still the supplier layer: chips, accelerators, networking and AI infrastructure components, rather than every company spending heavily to chase AI capacity.AI Leader
• AVGO / MRVL / AMD— AI semiconductor breadth remains one of the most important checks for next week. Broadcom and Marvell remain custom-silicon and networking reads, while AMD is the second-line appetite test for investors looking beyond Nvidia.AI Semis
• MRVL / FLEX— Marvell and Flex remain relevant on the index-flow side, with S&P 500 inclusion before the June 22 open. The theme is not only fundamentals: passive demand, positioning and benchmark flows can matter around inclusion windows.Index Flow
• AAPL— Apple stays under the consumer-AI and European regulatory lens. The market continues to watch whether AI feature timing, EU friction and upgrade-cycle expectations can coexist with Apple’s mega-cap quality premium.AI / EU
• ADBE— Adobe became one of the weaker large-cap software reads after the market digested leadership and execution concerns. In this tape, good software franchises still need clean guidance, AI monetization clarity and management stability.Software
• ARM— Arm was one of the stronger chip-related movers into the end of the week, helped by renewed AI semiconductor demand. The setup matters because Arm is often treated as a higher-beta read on AI compute architecture, not only a traditional chip stock.AI Chips
• NVO / LLY— Novo Nordisk and Eli Lilly remain the GLP-1 leadership pair. Novo’s oral semaglutide momentum keeps the obesity-pill theme active, while Lilly remains the direct competitive benchmark in a market that still rewards durability, access and scale.Obesity Drugs
• VRDN— Viridian remains one of the cleaner near-term biotech catalyst watches, with veligrotug under Priority Review and a June 30, 2026 PDUFA target date in thyroid eye disease.PDUFA Watch
• GILD / MRK— Gilead and Merck remain relevant after positive Phase 3 topline data for the once-weekly oral HIV combination islatravir/lenacapavir. Lower-burden chronic therapy remains one of pharma’s stronger durable themes.HIV / Phase 3
• TVTX— Travere Therapeutics remains worth watching after strength into the end of the week. In a selective biotech tape, analyst support and catalyst credibility can still attract momentum when the broader macro tape is not hostile.Biotech
• COGT / BBIO / VERA / CORT / CAPR— The FDA/catalyst basket remains central. The lesson has not changed: traders need catalyst timing, cash runway, label risk, dilution risk and regulatory quality together, not just a binary date on the calendar.Biotech FDA

• Weekend setup— June 13 is a Saturday update, so the market read comes from Friday’s close and the weekend news flow. The tone improved, but traders still need confirmation from oil, yields and futures when the new week opens.Market Setup
• SpaceX aftershock— SpaceX’s debut supported broad sentiment, but the public space basket did not behave uniformly. That is important: speculative appetite is alive, but not every space stock automatically benefits after the event becomes reality.Risk Appetite
• Retail demand— Reuters reported heavy retail involvement around the SpaceX IPO, with many individual investors chasing allocations or buying after the debut. That makes SPCX a useful retail-risk thermometer for the next few sessions.Retail Flow
• Iran deal hopes— The U.S. and Iran appear closer to a possible agreement, but the situation is not fully resolved. Reports of drone activity and tension near Hormuz mean the geopolitical risk premium can return quickly if talks stall.Geopolitics
• Oil relief— Brent and WTI moved lower on peace hopes, giving equities oxygen after the inflation shock. This helps airlines, travel, transports and consumer sentiment, but the trade remains fragile until Hormuz risk is clearly reduced.Oil
• PPI shock— BLS data confirmed hot upstream inflation: final demand PPI rose 1.1% in May, goods rose 2.8%, energy rose 10.7%, and final demand less foods, energy and trade services was up 5.1% over 12 months.Inflation
• CPI pressure— May CPI rose 4.2% year over year, with core CPI at 2.9%. That combination gives the market some relief on core inflation but keeps the energy-driven inflation problem very much alive.CPI
• Fed week ahead— The next major catalyst is the Federal Reserve meeting week. Investors are focused on how the newly led Fed discusses inflation, oil, financial conditions, the balance sheet and the possibility of future hikes.Fed
• ECB after the hike— The ECB has already moved toward a more hawkish inflation response, with the deposit facility moving to 2.25% from June 17. Europe remains exposed to the energy-price channel and weaker growth risk at the same time.Europe / ECB
• Rates still matter— Oil relief can help equities, but hot PPI and higher CPI make it hard for central banks to sound relaxed. That matters most for QQQ, SOXX, IWM, XBI and long-duration growth stories.Rates
• Biotech selectivity— A better risk tape helps XBI, but high rates still punish weak balance sheets. In biotech, clean data, credible FDA paths, enough cash and manageable dilution risk remain more important than broad sector hype.Biotech